Page last updated: 2024-11-06

5-fluoroorotic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-fluoroorotic acid: inhibits the dietary induction of serine dehydratase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-fluoroorotic acid : A pyrimidinemonocarboxylic that is orotic acid which is substituted by fluorine at position 5. It is used in yeast molecular genetics to detect expression of the URA3 gene, which encodes orotine-5'-monophosphate dicarboxylase. A yeast with and active URA3 gene converts 5-fluoroorotic acid to fluorodeoxyuridine, which is toxic to cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69711
CHEMBL ID1232805
SCHEMBL ID44527
MeSH IDM0041349

Synonyms (73)

Synonym
ai3-26398
4-pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-5-fluoro-
4-pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-
5-fluoroorotic acid (van)
4-pyrimidinecarboxylic acid, 5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-, monohydrate
orotic acid, 5-fluoro- (van)
5-fluorouracil-4-carboxylic acid
1,2,3,6-tetrahydro-2,6-dioxo-5-fluoro-4-pyrimidinecarboxylic acid
einecs 211-876-0
CHEMBL1232805
703-95-7
1,3,6-tetrahydro-2,6-dioxo-5-fluoro-4-pyrimidinecarboxylic acid
ent-26398
fluoroorotic acid
ro 2-9945
5-fluoroorotic acid
FOA ,
nsc 31712
5-fluoroorotate
orotic acid, 5-fluoro-
wln: t6vmvmj evq ff
mls000737636 ,
nsc-31712
wr 152520
nsc31712
4-pyrimidinecarboxylic acid,2,3,6-tetrahydro-2,6-dioxo-5-fluoro-
FOT ,
5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
smr000393806
5-fluoroorotic acid, 98.0%+
F-6300
5-foa
5-fluoro-2,4-dioxo-1h-pyrimidine-6-carboxylic acid
5-fluorouracil-6-carboxylic acid
F0382
NCGC00246927-01
5-fluoro orotic acid
7ia9ouc93e ,
unii-7ia9ouc93e
AKOS005207200
S9873
HMS2759G19
5-fluoroorotic acid [mi]
fluoroorotic acid, 5-
5-fluoro-6-carboxyuracil
ro-2-9945
5-fluoro-orotic acid
wr-152520
5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid
FT-0620427
SCHEMBL44527
DTXSID90220573
bdbm47470
5-fluoro-2,4-diketo-1h-pyrimidine-6-carboxylic acid
5-fluoranyl-2,4-bis(oxidanylidene)-1h-pyrimidine-6-carboxylic acid
cid_69711
fluoroorotic acid, ultra pure
5-fluoro-2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid
mfcd00042526
c5h3fn2o4
AC-10068
CS-W017535
4-pyrimidinecarboxylic acid,5-fluoro-1,2,3,6-tetrahydro-2,6-dioxo-
AS-14168
Q18207160
5-fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylicacid
SY001827
5-fluoro-2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid
5-fluoroorotic acid;5-foa
SB57260
EN300-746693
HY-W016819
PD069649

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To test the hypothesis that co-delivery of synergistic drug combinations in the same liposome provides a better anti-tumor effect than the drugs administered in separate liposomes, fluoroorotic acid (FOA) alone and in combination with irinotecan (IRN) were encapsulated in liposomes and evaluated for their anti-tumor activity in the C26 colon carcinoma mouse model."( Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Jerger, K; Kieler-Ferguson, HM; Riviere, K; Szoka, FC, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" FOA in different dosage forms was applied topically 2 to 3 times daily for 30 days."( Studies on the antimycotic activity of 5-fluoroorotic acid.
Golovinsky, E; Karamanov, G; Maneva, L; Nikolova, K, 1987
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency19.90540.140911.194039.8107AID2451
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency7.07950.631035.7641100.0000AID504339
phosphopantetheinyl transferaseBacillus subtilisPotency56.23410.141337.9142100.0000AID1490
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID504466
TDP1 proteinHomo sapiens (human)Potency11.58210.000811.382244.6684AID686978; AID686979
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency31.62280.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency28.18380.035520.977089.1251AID504332
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency25.11890.010039.53711,122.0200AID1479
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency25.92900.00419.984825.9290AID504444
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency3.54810.794321.275750.1187AID624246
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Janus kinase 2 (a protein tyrosine kinase)Homo sapiens (human)IC50 (µMol)6.87100.22304.23727.5320AID1699
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID545994Inhibition of Trypanosoma cruzi dihydroorotate dehydrogenase by isothermal titration calorimetry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
AID1132880Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 104 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132883Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 13 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132881Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 52 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (143)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (15.38)18.7374
1990's36 (25.17)18.2507
2000's48 (33.57)29.6817
2010's34 (23.78)24.3611
2020's3 (2.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.20

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.20 (24.57)
Research Supply Index4.98 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index56.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.20)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other144 (99.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]